MedTrace Logo

Adjuvant Pazopanib in Stage I NSCLC

NCT00775307 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2019-09-24

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy and safety of pazopanib compared with placebo in patients with T \< or = 5 cm, N0 (stage I according to TNM 2009) completely resected NSCLC.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

PAZOPANIB

400 mg/day (24 weeks)

DRUG

Placebo

Placebo 400 mg/day (24 weeks)

Sponsors & Collaborators

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Benjamin BESSE, Dr · Institut Gustave Roussy (IGR)

  • Jean-Charles SORIA, Pr · Institut Gustave Roussy (IGR)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2015-12-31
Completion
2016-04-18

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00775307 on ClinicalTrials.gov